Avant, Ainnova Bring AI Diabetes Tech to Mexico

AI is gaining ground in healthcare systems worldwide, with new deployments emerging in Mexico and beyond. Companies are moving from pilot stages to practical implementation, applying AI tools to improve diagnostics, streamline operations and address chronic disease management. These developments come as global care systems face mounting pressures from aging populations and rising rates of conditions like diabetes.

"AI is no longer theoretical and is fundamentally reshaping how providers operate," said Matt Hawkins, CEO, Waystar Holding Corp., citing recent research on AI’s role in revenue cycle management. “As healthcare organizations navigate growing complexity, the study shows they are relying on proven and trusted RCM software providers to deploy AI.”

With healthcare demand increasing, private equity and public markets are accelerating AI adoption. Tenner, Ellipsis Health and Autonomize AI raised a combined US$174 million in recent private funding, while publicly traded companies continue to roll out technologies in clinical and operational environments.

Avant Technologies, Inc. has announced plans to create a new entity focused on developing treatments for diabetes, a condition affecting over 500 million people globally. The company’s Vision AI platform is already in use for early detection of diabetic retinopathy and other diseases using retinal scans. Avant is evaluating joint ventures, acquisitions or partnerships to support its treatment ambitions.

Avant’s collaboration with Ainnova Tech has introduced free Vision AI screenings in Costa Rica’s Fischel and La Bomba pharmacy chains, with similar programs scheduled to launch in Mexico. The company plans to offer low-cost, automated diabetic eye screenings through pharmacies and clinics, aiming to increase access for underserved populations in the region. Vinicio Vargas, CEO, Ainnova Tech, said the initiative is designed to integrate pharmaceutical services, clinical specialists and AI technology into a single care pathway, with the goal of improving patient outcomes across Latin America.

To advance its strategy, Avant signed a non-binding letter of intent to acquire 100% of Ainnova Tech. The proposed acquisition would consolidate leadership, data assets and intellectual property under one public entity, streamlining operations ahead of a scheduled FDA pre-submission meeting in July. Engineers are finalizing a fully automated, cloud-connected retinal camera, designed to operate in low-resource settings without requiring specialist staff, an important factor for rural areas in countries like Mexico.

Beyond eye disease, Avant is piloting cardiovascular analytics across Latin America and validating a dementia-risk module that pairs AI algorithms with blood testing. These features plug into the company’s existing software platform, which is being positioned as a scalable system rather than a single-use application.

Other major healthcare players are also moving forward with AI integration. Eli Lilly has welcomed biotech firm RyboDyn into its Gateway Labs incubator to support the development of AI-driven immunotherapies. Palantir Technologies has partnered with TeleTracking to apply AI tools to hospital operations, improving patient flow and resource management. Philips published new regional data from Asia-Pacific revealing significant delays in care and underscoring the potential for AI to enhance decision-making and efficiency. The company reported that 89% of surveyed healthcare professionals believe AI can save lives through faster intervention.

Waystar’s findings reinforce a broader shift. A Forrester Consulting study revealed that 82% of healthcare leaders now consider AI essential to operations, with technology delivering gains of up to 37% in areas such as claim accuracy, payment speed, and workforce productivity.